Clinical Research Directory
Browse clinical research sites, groups, and studies.
Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Summary
The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% of the cases, the thrombectomy procedure makes it possible to retrieve either partially or completely the clot. Previous studies have analyzed the correlation between the composition of the thrombus and the etiology of stroke. Their discordant results do not yet make it possible to distinguish a particular profile of thrombus according to etiology. Other studies have shown a correlation between the proportion of red blood cells in a thrombus and the likelihood that it is visible in MRI or cerebral scanning. More recently, one study has demonstrated a correlation between the presence of lymphocytes in the thrombus and an atheromatous etiology. The main limitations of these studies are the small number of patients included, the high variability of conservation protocols and the absence of plasma data, which does not allow for research on the correlation between clot composition and plasma biomarkers.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1200
Start Date
2017-07-13
Completion Date
2028-01-01
Last Updated
2026-01-20
Healthy Volunteers
No
Interventions
Collection of thrombus that is responsible for stroke and blood sample
A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria : A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase \> 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis
Locations (12)
CHU de Bordeaux
Bordeaux, France
CHU Caen
Caen, France
Chu Limoges
Limoges, France
CHRU de Nancy
Nancy, France
CHU de Nantes
Nantes, France
Hôpital Lariboisière AP-HP
Paris, France
Centre hospitalier Sainte-Anne
Paris, France
Fondation Ophtalmologique A. de Rothschild
Paris, France
CHU de Rennes
Rennes, France
Hôpital Foch
Suresnes, France
Hôpital d'Instruction des Armées Sainte-Anne
Toulon, France
CHRU Tours
Tours, France